



UNIVERSITÀ
DEGLI STUDI
FIRENZE

FLORE

Repository istituzionale dell'Università degli Studi di Firenze

Gene polymorphisms/mutations relevant to abnormal spermatogenesis.

Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione:

Original Citation:

Gene polymorphisms/mutations relevant to abnormal spermatogenesis / F.Nuti; Csilla Krausz. - In: REPRODUCTIVE BIOMEDICINE ONLINE. - ISSN 1472-6483. - STAMPA. - 16:(2008), pp. 504-513.

Availability:

This version is available at: 2158/350373 since:

Terms of use:

Open Access

La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (<https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf>)

Publisher copyright claim:

(Article begins on next page)

Symposium: Genetic and epigenetic aspects of assisted reproduction

Gene polymorphisms/mutations relevant to abnormal spermatogenesis



Dr Francesca Nuti

Dr Nuti obtained her degree in biology at the University of Florence, Italy, where she continued her PhD studies in biochemistry, focusing on the regulation of phospholipase D by sphingosine 1-phosphate. Since 2005 she has worked as post-doctoral fellow in the group of Dr Krausz on the genetics of male infertility and cryptorchidism. She has recently received a fellowship from the Associazione Italiana Ricerca Cancro on the topic of testis cancer and continues to work in the research group of Dr Krausz.



Dr Csilla Krausz

Csilla Krausz is Senior Consultant in Andrology and Assistant Professor in Endocrinology at the Medical School of the University of Florence, Italy. Born in Hungary, she received her MD at the University of Florence in 1990 and completed her residency in Endocrinology at the same University in 1995. She worked at the Pasteur Institute (Paris, France) from 1997-2001 and obtained her PhD in Human Genetics in 2001 at the University 'Paris VII'. Since 1996 she has focused her research interest on Y chromosome genes, rearrangements, haplogroups, genetic risk factors related to impaired sperm production and cryptorchidism. She has over 60 publications in international journals and author of several book chapters.

Francesca Nuti, Csilla Krausz¹

Andrology Unit, Department of Clinical Physiopathology, Viale Pieraccini, 6, 50139 Florence, Italy

¹Correspondence: e-mail: c.krausz@dfc.unifi.it

Abstract

Despite the identification of an increasing number of candidate genes involved in spermatogenesis, the armamentarium of diagnostic genetic tests in male infertility remains extremely limited. A number of new causative mutations have been reported for hypogonadotropic hypogonadism but still the genetic diagnosis in this pathological condition is made only in about 20% of cases. The sole molecular genetic test that is routinely proposed in severe spermatogenic disturbances is screening for Yq microdeletion. The search for causative mutations in the Y chromosome, and in autosomal and X-linked genes, has mostly been unsuccessful. The paucity of gene mutations raises questions about the appropriateness of the currently used screening approaches. Among the proposed genetic risk factors, *gr/gr* deletion of the Y chromosome seems to be the most promising polymorphism. Other polymorphisms are awaiting further confirmation, whereas for some (*POLG*, *DAZL*, *USP26*, *FSHR*) a lack of association with abnormal spermatogenesis has now been ascertained. It is likely that some polymorphisms lead to testicular dysfunction only when in association with a specific genetic background or with environmental factors. Future large-scale studies with stringent study design may provide a more efficient way to identify clinically relevant genetic factors of male infertility.

Keywords: gene mutations, genetic risk factors, *gr/gr* deletions, male infertility, polymorphisms, spermatogenesis

Introduction

Spermatogenesis can be altered by different factors acting either at the pretesticular or directly at the testicular level.

Despite a significant improvement in the diagnostic work-up of infertile men, in about 50% of cases the cause of abnormal

spermatogenesis remains unknown and is called idiopathic infertility (Forti and Krausz, 1998). Considering the high number of predicted genes involved in male gametogenesis, it is highly likely that mutations or polymorphisms in candidate genes involved in spermatogenesis are responsible for the majority of idiopathic forms of spermatogenic disturbances.

To date, candidate spermatogenesis genes have been identified mainly through model organisms, expression studies, linkage analysis and cytogenetic findings (for review, see Matzuk and Lamb, 2002). Recently, the approaches of transcriptomics and proteomics have been applied in this field and open a new perspective in understanding male infertility (Ostermeier *et al.*, 2002; Martinez-Heredia *et al.*, 2006; Platts *et al.*, 2007).

This review focuses on data available in the literature on gene mutations/polymorphisms with ascertained or potential clinical relevance in human spermatogenesis.

Genes involved in the endocrine regulation of spermatogenesis

Spermatogenesis and steroidogenesis in the testis is regulated through the hypothalamic–pituitary–testicular axis and involves a number of hormones such as gonadotrophin-releasing hormone (GnRH), FSH, LH, testosterone, oestrogens and inhibin B.

Congenital gonadotrophin deficiency and spermatogenic failure

Mutations in genes responsible for the migration of GnRH neurons, such as anosmin-1 (*KAL1*), fibroblast growth factor receptor 1 (*FGFR1*), G-protein-coupled prokineticin receptor-2 (*PROKR2*), prokineticin-2 (*PROK2*) or mutations in the gonadotrophin-releasing hormone receptor (*GnRH-R*) gene or G-protein-coupled receptor 54 (*GPR54*) cause congenital hypogonadotrophic hypogonadism (for review, see Trarbach *et al.*, 2007). Depending on the type of gene involved, these genetic anomalies can be associated with anosmia (Kallmann syndrome) or normosmia. Although sporadic cases are more frequent, families with Kallmann syndrome have been reported with X-linked, autosomal dominant or recessive modes of inheritance. The penetrance of the same mutation may vary in different family members, leading to a wide phenotype spectrum including the presence/absence of non-reproductive and non-olfactory disorders. Gonadotrophin deficiency can also be due to mutations of the beta subunits of LH and FSH. To date, only three distinct FSH and two LH beta subunit gene mutations have been described (Huhtaniemi, 2006). Given that the screening for mutations in all the above-described genes provides the identification of mutations only in about 20% of cases, additional genetic causes are expected to be discovered in the future. The diagnosis of congenital hypogonadotrophic hypogonadism is normally made before adulthood since it is associated with delayed puberty. In adulthood, spermatogenesis can be relatively easily induced by hormonal treatment; congenital hypogonadotrophic hypogonadism therefore represents a peculiar group of treatable forms of spermatogenic disturbance of genetic origin.

Steroid receptor gene mutations

The crucial role of androgens and oestrogens in the endocrine regulation of spermatogenesis is well known; therefore, genes of their receptors are a logical target for mutational analysis in infertile males.

The androgen receptor (AR) is a ligand-activated transcription factor that is encoded by the *AR* gene located on the long arm of the X chromosome (Xq11–q12). A large number of mutations in the *AR* gene have been identified worldwide and are available at the Androgen Receptor Gene Mutations Database (Gottlieb *et al.*, 2004). Functional assays have demonstrated that a significant number of these mutations result in lower ligand binding or transactivation potential of the mutant receptor molecule. Mutations in the *AR* gene result in mild-to-complete androgen insensitivity. The phenotypic features of complete androgen insensitivity syndrome are female external genitalia and absence of pubic hair. In partial androgen insensitivity syndrome, several different phenotypes are evident, ranging from predominantly female phenotype (female external genitalia, pubic hair with or without clitoromegaly, and partially to completely fused labia) through ambiguous genitalia to predominantly male phenotype with micropenis, perineal hypospadias and cryptorchidism (Quigley *et al.*, 1995). The later phenotype is also termed as Reifenstein syndrome (Quigley *et al.*, 1995). Patients with mild androgen insensitivity syndrome have male infertility as their primary or even sole symptom.

Only a few mutations have been reported in male infertility (Gottlieb *et al.*, 2004; Ferlin *et al.*, 2006) and most of them have resulted in the reduction of transactivation potential of the mutant protein. In a recent screening of 1517 azo-oligozoospermic individuals, 26 patients carrying *AR* mutations (20 different mutations) (1.7%) were found, and none in the control group (Ferlin *et al.*, 2006; Rajender *et al.*, 2007). There has been no correlation between the type of mutation and the subtype of infertility (azoospermia, oligozoospermia or oligoteratozoospermia). Moreover, the previously proposed high androgen sensitivity index seems not to be able to predict an accurate selection for *AR* mutation screening. Apart from the difficulty in preselecting patients for the analysis, the need for routine testing in infertile subjects is further questioned by other reports in which none or very few mutations were detected in a large series of idiopathic infertile men (Singh *et al.*, 2006; for review see Rajender *et al.*, 2007).

The analysis of polymorphic regions in exon 1 of *AR* has been the subject of a large number of publications (Tut *et al.*, 1997; Dowsing *et al.*, 1999; von Eckardstein *et al.*, 2001; Rajpert-de Meyts *et al.*, 2002; Foresta *et al.*, 2005). The polymorphic (CAG)_n codes for a polyglutamine whereas the (GGC)_n repeat codes for a polyglycine stretch. It has been demonstrated for the (CAG)_n repeats in in-vitro experiments that the length of the polyglutamine tract, while remaining within the polymorphic range, is inversely correlated with the transactivation activity of the receptor (Tut *et al.*, 1997). Concerning the (GGC)_n repeat, a recent report showed that *AR* with GGN repeat lengths other than the most common one of 23 have lower transactivating capacity (Lundin *et al.*, 2007).

Despite promising in-vitro data, the initial observations of a significant association between relatively long CAG repeats and

impaired sperm production (Dowsing *et al.*, 1999) have not been confirmed by subsequent studies (for review see Asatiani *et al.*, 2003). Similarly, it is still under question whether the (GGC)_n repeat has a pathogenic role in abnormal spermatogenesis (see Krausz and Giachini, 2007).

Discrepancies in the literature maybe the consequence of: (i) ethnic differences (the association seems to be more consistent in Asiatic populations); (ii) the heterogeneity of the control (unselected men, proven fertile men or normospermic men) and of the infertile (different inclusion criteria) groups; (iii) inadequate sample size (especially in the first positive studies).

In conclusion, mutation screening of neither the *AR* nor the CAG repeats can be proposed as a routine diagnostic test in patients with abnormal spermatogenesis. Mutations of *AR* are rare and many of the mutations described in infertile men still need to be characterized for their functional consequences. Concerning CAG repeat length, this polymorphism is an unlikely risk factor for male infertility if we consider large studies only. However, the role of CAG repeat length in modulating androgen action is more evident in patients affected by hypogonadism (for example subjects affected by Klinefelter syndrome) and its analysis could be useful for the definition of thresholds at which testosterone treatment should be initiated, and to personalize the dosage of substitutive testosterone therapy (Zitzmann *et al.*, 2004).

Oestrogen receptor

Although human and animal models have shown an association between oestrogen insufficiency and abnormal spermatogenesis, little attention has been paid to the role of oestrogen receptor (*ESR*) gene mutations or polymorphisms in male infertility.

The physiological responses to oestrogens are known to be mediated by at least two functional isoforms of *ESR*, namely *ESR1* and *ESR2*, encoded by two different genes in different chromosomes (6q25 and 14q23–24, respectively). Both receptors share the common structure of the steroid/thyroid hormone nuclear receptor, differing in the C-terminal ligand-binding domain and in the N-terminal transactivation domain (O'Donnell *et al.*, 2001). Besides these two isoforms a third membrane receptor has been reported in different cellular models including human spermatozoa (Luconi *et al.*, 2002). This membrane receptor is probably involved in the stimulatory effect on sperm capacitation, acrosome reaction, and fertilizing ability of 17β-oestradiol and environmental oestrogens observed in mouse spermatozoa (Adeoya-Osiguwa *et al.*, 2004).

To date only one patient with an inactivating mutation in the *ESR1* gene (Smith *et al.*, 1994), and four patients with aromatase (*CYP19*) deficiency have been reported (Morishima *et al.*, 1995; Carani *et al.*, 1997; Deladoey *et al.*, 1999; Maffei *et al.*, 2004). The phenotypes of these patients are rather heterogeneous, ranging from normal sperm concentration but reduced sperm viability in cases of the *ESR1* mutation, to oligozoospermia and bilateral cryptorchidism in cases of aromatase deficiency (Carani *et al.*, 1997; Maffei *et al.*, 2004).

The human *ESR1* gene encodes a protein of 595 amino acids with a molecular mass of about 66 kDa. Genetic screening of the *ESR1* gene locus has revealed the existence of several

polymorphic sites. The most widely studied are the *PvuII* (T397C) and *XbaI* restriction fragment length polymorphisms in intron I and the (TA)_n variable number of tandem repeats within the promoter region of the gene (Gennari *et al.*, 2005). Recently a possible relationship between *ESR1* polymorphisms and male infertility has been reported in Greek and Japanese populations (Kukuvitis *et al.*, 2002; Suzuki *et al.*, 2002). However, due to the relatively small study populations in both studies, the interpretation of these data remains difficult.

The most promising polymorphism is the (TA)_n variable number of tandem repeats within the promoter region. The distribution of the TA genotype is not different between controls and patients, therefore this polymorphism cannot be considered a risk factor for male infertility. However, it has a significant effect on sperm output in both normospermic and infertile men (Guarducci *et al.*, 2006). The number of TA repeats showed a significant inverse correlation with sperm count, and consequently men with a higher TA repeat number on both alleles have significantly lower sperm production. A plausible explanation would be that not only a deficit of oestrogens, but also an exaggerated oestrogen action related to this genetic variant (eventually combined with environmental factors), can be deleterious. Since the individual sensitivity to xenoestrogens may depend on the type of *ESR1*, the screening for this polymorphism may be useful in subjects with high exposure to xenoestrogens. Another interesting *ESR1*-gene-related polymorphism is the specific haplotype AGATA, resulting from the allelic combination of five single nucleotide polymorphisms (SNP) situated in a 50 Kb haplotype block of *ESR1*. The AGATA haplotype in the Japanese population has been reported as risk factor for cryptorchidism (Yoshida *et al.*, 2005), whereas in the Italian population the tag SNP of the AGATA haplotype (SNP12) has a significant protective effect (Galan *et al.*, 2007). The discrepancy between the Italian and the Japanese study may be related to genuine ethnic differences and/or different environmental conditions. A role for *ESR2* gene SNP in male infertility has also been proposed recently (Aschim *et al.*, 2005; Galan *et al.*, 2005). Given that for each type of variant and haplotype there are only sporadic studies, it is important to confirm their clinical significance in other independent study populations. It would be especially interesting to verify their effect on spermatogenic potential in relation to different grades of exposure to xenoestrogens.

Genes involved in common cell functions

Studies on genes involved in common cell functions that are relevant also for normal spermatogenesis are relatively few and are mainly single studies, with the exception of the mitochondrial DNA polymerase γ (*POLG*) and the methylenetetrahydrofolate reductase (*MTHFR*) genes. To date, only polymorphisms with little or no clinical relevance have been described. The *POLG* gene CAG polymorphism (with a major allele at 10 repeats) has been the subject of an extensive debate in the last few years. *POLG* is the sole polymerase for mitochondrial DNA (mtDNA) and impaired activity of this protein leads to mitochondrial dysfunction through accumulation of mtDNA mutations. Lack of functional *POLG* may therefore lead to several cellular dysfunctions including altered cell proliferation. Rovio *et al.* (2001) proposed an association between the absence of the common 10 CAG allele and male infertility in a relatively

small group of infertile and fertile men. Subsequent studies in populations from Europe (Krausz *et al.*, 2004; Akinin-Seifer *et al.*, 2005; Brusco *et al.*, 2006) and New Zealand (Harris *et al.*, 2006) failed to confirm this first observation. Similarly, the proposed association with unexplained infertility (Jensen *et al.*, 2004) was also rejected after having ruled out interpretation bias (Krausz *et al.*, 2004). It is therefore clear that the *POLG* CAG polymorphism has no clinical significance either for idiopathic or for 'unexplained' male infertility.

MTHFR is one of the key enzymes in folate metabolism and reduces 5,10-methylenetetrahydrofolate to its biologically active form 5-methyltetrahydrofolate. The C677T polymorphism of the *MTHFR* gene has been extensively analysed in infertile patients from different populations (Bezold *et al.*, 2001; Ebisch *et al.*, 2003; Stuppia *et al.*, 2003; Singh *et al.*, 2005; Park *et al.*, 2005). The C677T mutation decreases MTHFR activity and it leads to a decrease in folate levels and an increase in homocysteine levels in the blood. Altered folate metabolism influences DNA methylation, and subjects with homozygous mutation 677TT have a lower level of genomic DNA methylation than controls (Stern *et al.*, 2000). Since aberrant DNA and protein methylation is likely to affect spermatogenesis, the C677T represent a logical target for mutation screening in patients with impaired spermatogenesis; however, results are discordant. Studies from Indian, African and south-east Asian populations agree that *MTHFR* gene polymorphism is significantly associated with abnormal spermatogenesis, whereas European studies have obtained conflicting results. It is also not clear if only homozygous (TT) or also heterozygous (CT) *MTHFR* polymorphism are of clinical relevance. The most likely explanation is that the polymorphism is relevant

only in specific environmental conditions, such as low dietary intake of folates. The pharmacogenomic correlate of the above-mentioned association studies is that idiopathic infertile carriers of the 677TT genotype may potentially benefit from folic acid supplementation.

Genes involved in specific spermatogenic functions

Autosomal and X-linked genes

A number of spermatogenesis autosomal and X-linked candidate genes have been identified (mainly based on animal models) and they represent the most obvious targets for mutation analysis in men with spermatogenic failure. However, the search for candidate gene mutations has not led to the identification of confirmed novel causative mutations for impaired sperm production. The few available examples of 'causative mutations' are reported in **Table 1**, and they are mainly related to the endocrine control of spermatogenesis. In contrast, the number of genetic variants proposed as risk factors for male infertility are constantly increasing. However, in many cases only sporadic data are available and when more studies are published on the same polymorphism the results are often contradictory. Inadequate sample size, pathogenetic heterogeneity of infertility, inappropriate control subjects and ethnic/geographic differences (probably also related to environmental factors) may be responsible for discrepancies among case-control studies. **Table 1** contains a comprehensive list of candidate genes that were screened for mutations in

Table 1. Summary of mutations with cause-effect relationship (causative) and polymorphisms proposed as risk factors for abnormal spermatogenesis.

Mutation	Gene Endocrine regulation of spermatogenesis	Specific spermatogenic function	Common cell function
Causative	<i>AR, KAL-1, FGFR1, PROK2, PROK2R, GnRH, GnRHR, GPR54, FSH, LH, ESR1, CYP19</i>	<i>USP9Y, SYCP3</i>	
Polymorphisms (single study)	<i>CYP19A1, NRIP1</i>	<i>GRTH, CREM-ACT, KIT-KITLG, HANP1/HIT2, PUMILIO2, BOULE</i>	<i>GSTM1, PHGPx, BRCA2, MS, MTRR, APOB, SDHA</i>
Polymorphisms (more than one study)	<i>AR, FSHR, ESR1, ESR2</i>	<i>DAZL, PRM1-PRM2, TNP1-TNP2, USP26</i>	<i>POLG, MTHFR</i>

For gene polymorphisms indicated in bold, a role as 'risk factor' has not been confirmed in Caucasian populations. Genes: *ACT* = activator of *CREM* in the testis; *APOB* = apolipoprotein B; *AR* = androgen receptor; *BRCA* = breast cancer; *CREM* = cAMP-responsive element modulator; *CYP19A1* = CYP19 aromatase; *DAZL* = deleted azoospermia-like; *ESR* = oestrogen receptor; *FGFR1* = fibroblast growth factor receptor 1; *FSHR* = FSH receptor; *GnRH* = gonadotrophin-releasing hormone; *GnRHR* = gonadotrophin-releasing hormone receptor; *GPR54* = G-protein-coupled receptor 54; *GRTH* = gonadotrophin-regulated testicular helicase; *GSTM1* = glutathione *S*-transferase M1; *HANP1/HIT2* = histone H1-like, nuclear protein 1; *KAL1* = Kallmann syndrome 1; *KIT* = v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue; *KITLG* = KIT ligand; *MS* = methionine synthase; *MTHFR* = 5,10-methylenetetrahydrofolate reductase; *GSTM1* = glutathione *S*-transferase M1; *PHGPx* = phospholipid hydroperoxide glutathione peroxidase; *MTRR* = MS reductase; *NRIP1* = nuclear receptor interacting protein 1; *POLG* = mitochondrial DNA γ -polymerase; *PRM* = protamine; *TNP* = transition nuclear protein; *PROK2* = prokineticin-2; *PROKR2* = G-protein-coupled prokineticin receptor-2; *SDHA* = succinate dehydrogenase, subunit A; *SYCP3* = synaptonemal complex protein 3; *USP26* = ubiquitin-specific peptidase 26; *USP9Y* = ubiquitin-specific protease 9.

infertile men. The few mutations with a cause–effect relationship with abnormal spermatogenesis are already of clinical use in selected groups of patients (congenital hypogonadotropic hypogonadism, androgen resistance), whereas the clinical significance of polymorphisms (risk factors for abnormal spermatogenesis) and some of the causative mutations are still under debate. A few genes among the most promising ones have been selected for further discussion.

Based on data from model organisms and expression studies, genes expressing the highly conserved family of proteins DAZ, DAZL and BOULE have been proposed as major spermatogenesis candidate genes in humans. The *DAZL* gene is an autosomal homologue of the Y-chromosomal *DAZ* (deleted in azoospermia) gene cluster and maps to chromosome 3p24 (Yen *et al.*, 1996). All three family members encode RNA-binding proteins with important roles in spermatogenesis (Yen, 2004). Recently, new insights into the role of DAZL in synapsis formation in meiosis have been obtained (Reynolds *et al.*, 2007) based on the observation that *Sycp3* is a target of DAZL-mediated translation. Despite extensive mutation screening in the *DAZL* gene, to date only one homozygous mutation in exon 2, in a position close to the RNA-binding domain of the protein, has been found in an azoospermic man (Tung *et al.*, 2006b). On the other hand, a high number of SNP have been identified ($n = 85$) and are mainly located in introns or in the 5 and 3 untranslated regions. The only exonic SNP reported as a susceptibility factor to oligo/azoospermia in the Chinese population is located in exon 3 (T54A) (Teng *et al.*, 2002). Surprisingly, this variant was not even found in Caucasians (Bartoloni *et al.*, 2004; Becherini *et al.*, 2004; Tschanter *et al.*, 2004). Specific haplotypes, based on the combination of SNP in noncoding regions, have been reported to be associated with sperm count (Tung *et al.*, 2006a) or with spermatogenic failure (Teng *et al.*, 2006). However, given the discrepancy between these two studies, it remains to be established if such an association does exist and if it is also present in Caucasians. No clinically relevant mutations for the *BOULE* (*BOLL*) gene have been reported (Lepretre *et al.*, 2004; Westerveld *et al.*, 2005a). Recently, another evolutionary conserved protein, pumilio (*PUM2*), has been screened for mutations in patients with reduced sperm count (Kusz *et al.*, 2007). Despite a clear role of pumilio proteins in germ cell development and the specific expression pattern of *PUM2* in the testis and ovary, the screening did not reveal any causative mutations.

The *SYCP3* gene, located on chromosome 12, encodes a DNA-binding protein as a component of the synaptonemal complex that regulates the synapsis between homologous chromosomes during meiosis of germ cells (Yuan *et al.*, 2000). According to the predicted phenotype based on the function of this protein, a null mutation of *Sycp3* in mice causes azoospermia with meiotic arrest. A mutation analysis in highly selected patients affected by maturation arrest identified a 1-bp deletion (643delA) that results in a premature stop codon and truncation of the C-terminal, coiled-coil-forming region of the SYCP3 protein. The same mutation was found in two of 19 patients (Miyamoto *et al.*, 2003). Unfortunately, no causative mutations were observed in subsequent European studies in a total of 70 selected patients (Martinez *et al.*, 2007) with a similar testicular phenotype to that reported in previously by Stouffs *et al.* (2005a). These later findings exclude a relevant role for *SYCP3* mutations in the aetiopathogenesis of spermatogenic arrest.

Another newly discovered component of the synaptonemal complex, the *FKBP6* gene (located in chromosomal region 7q11.23), was screened in 51 men with non-obstructive azoospermia through direct sequencing methods (Westerveld *et al.*, 2005b). Only two heterozygous mutations (T173T and R183C) were identified that are likely to disrupt FKBP6 protein function. However, both mutations were also found in normospermic controls, indicating that one *FKBP6* allele appears to be sufficient for normal spermatogenesis. In conclusion, despite careful selection of patients with relatively homogeneous phenotype similar to that expected based on of mouse model, genetic defects of these two genes are an uncommon cause of azoospermia in humans.

Genes involved in compaction of the sperm nucleus are relevant for correct spermiogenesis. This remarkable repackaging event is related to the requirement for a unique chromatin architecture that would enable a specific transcription schedule after fertilization. Premature translation of *PRM1* mRNA causes precocious nuclear condensation and arrests spermatid differentiation in mice (Lee *et al.*, 1995), and the disruption of either the *Prm1* or the *Prm2* gene in mice leads to haploinsufficiency, abnormal chromatin compaction, sperm DNA damage, and male infertility. Although reduction of protamine-2 has been reported in infertile men, mutations in the *PRM2* gene have not been reported in association with reduced PRM2 content (Tanaka *et al.*, 2003; Carrell *et al.*, 2007). Nishimune and coworkers (Tanaka *et al.*, 2003) identified a number of SNP in both the *PRM1* and the *PRM2* genes in a large number of infertile men presenting mainly azoospermia, compared with proven fertile controls. No association between any of the SNP and infertility was observed. However, one mutation in the *PRM2* gene induced a nonsense codon C248T and was present in heterozygosity in one azoospermic patient. Unfortunately, the testis histology of the patient is unknown and this makes it difficult to interpret the consequences of this mutation. In a recent study, a highly selected group of infertile patients was screened for *PRM1* gene mutations (Iguchi *et al.*, 2005). A novel SNP, G197T, in a highly conserved region of the gene was identified in 3/30 patients. Based upon the absence of this SNP in over 700 individuals, and the recent confirmatory data from Ravel *et al.* (2007), it appears to be a promising new genetic risk factor for a specific subgroup of infertile patients with abnormal sperm DNA fragmentation and/or teratozoospermia.

Page and collaborators (Wang *et al.*, 2001) reported an unexpectedly high number of X-linked genes expressed in the testis. This finding would suggest an important role for X-linked genes in male gametogenesis. However, up to now, only one X-linked gene (*AR*) has been investigated in large-scale studies (see the section on steroid receptor gene mutations), whereas two genes, *USP26* and *TAF7L*, have been screened in relatively small study populations. The *USP26* gene is located on the long arm of the X chromosome (Xq26.2) and belongs to the family of deubiquitinating enzymes that might be involved in histone removal and in the regulation of protein turnover in germ cells. It is specifically expressed in the testis throughout all stages and it was first proposed as having a key function in the early stages of spermatogenesis (Stouffs *et al.*, 2005b). Sequence variants have been found mainly in azoospermic men (Paduch *et al.*, 2005; Stouffs *et al.*, 2005b) and a special cluster of three SNP have been proposed as potential genetic causes for spermatogenic failure. However, the finding of the same cluster in one man with normal spermatogenesis (Stouffs *et al.*, 2006a) and its high

frequency in men from sub-Saharan Africa and south and east Asia (Ravel *et al.*, 2006) has questioned the pathogenic role of this specific haplotype. For the other X-linked gene *TAF7L*, which is homologous to the autosomal transcription factor gene *TAF7* and is also expressed specifically in the testis, no causative mutations were found in a small study population (Stouffs *et al.*, 2006b). However, due to the low number of patients tested, the role of *TAF7L* mutations in spermatogenic failure remains to be established.

Another interesting group of candidate genes are retrogenes. Retrogenes originate from their progenitor genes by retroposition. Several retrogenes reported in recent studies are autosomal, originating from X-linked progenitor genes, and have evolved a testis-specific expression pattern. During male meiosis, sex chromosomes are segregated into a so-called 'XY' body and are silenced transcriptionally. The silencing of the X chromosome during male meiosis could therefore be the driving force behind the retroposition of X-linked genes to autosomes during evolution (Wang, 2004). Despite their potential interest, no large-scale analysis has been performed in testis-specific retrogenes so far.

The Y chromosome: gene mutations and polymorphisms

The long arm of the human Y chromosome hosts a number of genes involved in spermatogenesis, and several types of recurrent Yq deletions are firmly associated with spermatogenic failure (for review see McElreavey and Krausz, 1999; Krausz *et al.*, 2003; Skaletsky *et al.*, 2003). However, such observations do not allow attribution of spermatogenic function to any particular Y-chromosome-encoded protein because each of these deletions removes multiple genes. Despite the efforts of many research laboratories (results from around 2000 subjects screened for gene-specific deletions have been published) only four cases of confirmed isolated Yq gene mutation/deletion have been reported to date, and all are related to the *AZFa* region (Brown *et al.*, 1998; Sun *et al.*, 1999; Krausz *et al.*, 2006). Since only one laboratory has performed mutation screening in *AZF* genes with direct sequencing (one mutation found out of 560 men), it is difficult to estimate the frequency of point mutations in *AZF* genes.

The rarity of single *AZF* gene deletions is in sharp contrast with the relatively high frequency of *AZF* deletions (classically divided into three azoospermia factor regions: *AZFa*, *AZFb* and *AZFc*; Vogt *et al.*, 1996), which represent the most frequent molecular genetic cause of azoospermia and severe oligozoospermia ($<5 \times 10^6$ spermatozoa/ml) (for a review see Krausz *et al.*, 2003). A likely explanation is that the peculiar structure and the sequence organization of the Y chromosome make this chromosome prone to the loss of large regions such as the *AZF* gene regions. The complete removal of the *AZFa* and *AZFb* regions is associated with the severe testicular phenotype Sertoli cell-only syndrome, and spermatogenic arrest, respectively. The complete removal of the *AZFc* region causes a variable phenotype, which may range from azoospermia to oligozoospermia. The above-reported genotype/phenotype correlation confers to Y-deletion analysis a prognostic value for testicular sperm retrieval (Krausz and Degl'Innocenti, 2006). The deletion phenotypes suggest that the *AZFa* and *AZFb* regions contain at least one gene with essential spermatogenic

function, whereas genes of the *AZFc* region are more likely to affect the efficiency of spermatogenesis.

The *AZFa* region contains two genes, namely *DDX3Y* (former *DBY*) and *USP9Y*, and the removal of both genes is associated with the complete absence of spermatogenic cells in the testis. *USP9Y* is the only Yq gene for which isolated mutations have been reported and no cases of confirmed isolated *DBY* deletions have been reported.

In three cases the exact breakpoint of the deletions has been defined (Sun *et al.*, 1999; Krausz *et al.*, 2006): the first, a 4-bp splice-donor site deletion resulting in severely truncated protein (Sun *et al.*, 1999); the second, the removal of the last 13 exons; and the third, the loss of the promoter and the first 28 exons (Krausz *et al.*, 2006). The first patient described by Sun *et al.* (1999) presented azoospermia with a testis histology showing hypospermatogenesis with occasional tubules containing only premeiotic or meiotic germ cells (spermatogenic arrest). This finding led to the conclusion that although complete absence or significant truncation of *USP9Y* protein is not enough to produce the full *AZFa* phenotype, it still causes azoospermia. In two unique cases of deletions removing part of the *USP9Y* gene, the phenotype was moderate oligoasthenoteratozoospermia and in both cases the mutations were spontaneously transmitted (Krausz *et al.*, 2006). In one family the transmission occurred through two generations and represents the first description of a familial case of partial *AZFa* deletion. The second deletion was naturally transmitted from a subfertile father to his son, conceived while the couple were on a waiting list for assisted reproduction techniques. The phenotype of the two last cases clearly indicates that the protein is not required for the acquisition of sperm fertilizing ability, and, during human spermatogenesis, its role is more likely to be a 'fine-tuner', which improves efficiency rather than a provider of essential function. Moreover, it suggests that *DDX3Y* is the most likely candidate for the *AZFa* deletion phenotype.

Apart from the *AZF* genes, the *TSPY* (testis-specific protein, Y-linked) gene may also be involved in spermatogenesis. On the basis of the expression pattern of *TSPY*, the homology of *TSPY* with *SET* (oncoprotein) and the interaction between *TSPY* and cyclin B Lau (1999) suggests a possible role of *TSPY* in regulating spermatogonia to enter meiosis. Its role in male infertility remains to be established. It is possible that copy-number variations may influence spermatogenic potential; however, preliminary data showing an association with *TSPY* dosage by Vodicka *et al.* (2007) needs to be replicated by validated methods and on a large group of patients/controls.

Polymorphisms in the *AZFc* region

Apart from the classical *AZF* deletions, new types of Yq rearrangements have recently attracted the attention of geneticists and andrologists (for review see Noordam and Repping, 2006). The peculiar structure of the *AZFc* region (**Figure 1**) allows a series of rearrangements including the formation of partial deletions, deletion/duplications and partial duplications. Among them the most relevant is termed the 'gr/gr' deletion (Repping *et al.* 2003) and removes half of the *AZFc* content including two copies of the major *AZFc* candidate gene called *DAZ* (Reijo *et al.*, 1995). This type of deletion is a significant




Figure 1. The upper part is a schematic representation of the Y chromosome. Genes of the three azoospermia factor (*AZF*) regions are listed. Deletions of these regions result in spermatogenic failure. Multi-copy genes are in italics, whereas non-italic letters indicate single-copy genes. Underlined genes are expressed exclusively in the testis, whereas non-underlined are expressed ubiquitously. Transcription unit families are indicated with an asterisk. *AZFb* deletions (two subtypes) overlap with the *AZFc* region. *Yq* = long arm of the Y chromosome; *Yp* = short arm of the Y chromosome; *PAR* = pseudoautosomal region; *MSY* = male-specific Y with an extension of 63 Mb. The lower part shows the *AZFc* region in detail. This region contains a number of repeated sequences with the same orientation (arrows with the same shading) which through intrachromosomal recombination may lead to deletions. The clinically relevant *gr/gr* deletion is shown.

risk factor in some populations but apparently not in others (for review see Krausz and Giachini, 2007). Contradictory results are likely to derive from methodological differences together with inappropriate control selection (only in a minority of studies are the controls normospermic men, and controls and patients are not matched for ethnic background in highly mixed populations such as Paris, the south of France and Brazil). Moreover, the majority of studies use sequence-tagged sites plus/minus polymerase chain reaction analysis, which alone does not provide information about the type of missing gene copies and about deletion/duplication events. For this reason the ideal methodology should be a combined analysis based on a first-step sequence-tagged site plus/minus analysis followed by a confirmatory dosage analysis restricted to the samples with suspected deletions, as described by Giachini *et al.* (2005). In the authors' extended series of patients/controls (almost 1000 subjects), after having performed a detailed molecular analysis and compared the frequencies between normospermic and infertile men, the *gr/gr* deletion proved to be a significant risk factor for abnormal spermatogenesis (Giachini *et al.* 2005; and unpublished data). The *gr/gr* deletions have been mainly found in oligozoospermic men but in very few cases (2/460) they have also reported in normospermic subjects. Among a number of plausible explanations for the heterogeneous phenotype the following explanations are postulated: (i) The presence of polymorphisms or mutations in the autosomal homologue of the *DAZ* gene *DAZL* (Becherini *et al.*, 2004). However,

similar to the *AZFc*-deleted patients, no new mutations were found in the entire coding region of the *DAZL* gene except the polymorphic Thr12-Ala change (T12A), which, due to its relatively high frequency in the normospermic group, does not seem to have any modulating effect (Giachini *et al.*, 2005); (ii) The type of missing gene copies (*DAZ1/DAZ2* and *CDY1A* versus *DAZ3/DAZ4* and *CDY1B*); and (iii) The Y background (Y haplogroups). Therefore, it is likely that only a combined analysis will provide a tool for distinguishing between 'neutral' and 'pathogenic' types of deletions.

Recently, Yen and collaborators proposed that not only a reduction but also an excess of *AZFc* gene dosage could be deleterious for spermatogenesis (Lin *et al.*, 2007). The authors report that partial *gr/gr* duplication (with a consequent double dosage of genes situated inside the region) is a significant risk factor for reduced sperm count in the Chinese population. Further studies are needed to define whether *gr/gr* duplication is a risk factor for reduced sperm count in other populations.

In conclusion, due to the above-mentioned biases (study design, ethnic differences, methodology), it is impossible to perform a reliable meta-analysis of published data on *gr/gr* deletion. In the few studies with appropriate control selection and confirmation of deletions, *gr/gr* deletions are clearly a risk factor for spermatogenic disturbances (Repping *et al.*, 2003; Giachini *et al.*, 2005). Although it is not understood why in certain individuals

the deletion does not affect spermatogenesis, it is likely that Y background (Y haplogroups) plays an important modulating role. In fact, certain Y haplogroups contain constitutive gr/gr deletions and are diffused in certain populations, indicating that other compensatory mechanisms may exist on certain Y backgrounds (Repping *et al.*, 2006). Given that fathers bearing gr/gr deletion will obligatorily transmit not only the deletion but also their entire Y chromosome (with or without compensatory structures) to their male offspring, it is likely that their sons will have a similar spermatogenic disturbance in the future. Thus, gr/gr deletion screening should be introduced among genetic diagnostic tests, especially prior to assisted reproduction techniques.

Conclusions

Thanks to the large-scale availability of molecular genetic tools and to the identification of an increasing number of candidate genes, the field of genetics of male infertility is rapidly evolving. However, the advancement in basic research has not been followed by a substantial increase in genetic diagnostic tests. Twelve years on from the description of the three AZF regions (Vogt *et al.*, 1996), the sole molecular genetic test that is routinely proposed in severe oligo/azoospermic men is the screening for Yq microdeletions. The screening for mutations in genes with predicted specific spermatogenic function has not allowed the identification of clinically relevant mutations. Whether this is due to the real rarity of gene mutations, or to the inappropriateness of the currently used approaches, remains to be established. Recently, Krawetz proposed a new strategy based on sperm transcript profiling that may identify abnormal molecular pathway(s) in specific pathological conditions, such as for example teratozoospermia (Platts *et al.*, 2007). Information obtained from microarray analysis will allow the selection of candidate genes to be screened for mutations in a specific subset of patients with well-defined pathological phenotypes.

Another promising approach, based on the reverse transcription of full length mRNA from spermatozoa, has been proposed by Matzuk and colleagues (Yatsenko *et al.*, 2006) and should accelerate the search for clinically relevant mutations. Given the origin of mRNA (haploid germ-cell-expressed genes), the usefulness of both approaches is limited to the detection of genetic defects involved in the post-meiotic maturation of germ cells.

As far as polymorphisms are concerned, the currently used case-control studies are often sources of contradictory results. The lack of reproducibility can be due to different factors already pointed out in the text. A substantial advancement will likely be achieved by the use of new technologies (microarrays) and from multicentre studies (high numbers of well-selected controls and patients of different ethnic origin) able to increase both the efficiency of the screening and the reliability of the results.

Acknowledgements

We thank AIRC (Associazione Italiana per la Ricerca sul Cancro) for the support of FN. The authors' studies were supported by the Italian Ministry of Education and Research (MIUR). The authors report no financial or commercial conflicts of interest.

References

- Adeoya-Osiguwa SA, Fraser LR 2004 Environmental estrogens and sperm function. *Human Reproduction* **19**, 216–217.
- Aknin-Seifer IE, Touraine RL, Lejeune H *et al.* 2005 Is the CAG repeat of mitochondrial DNA polymerase gamma (POLG) associated with male infertility? A multi-centre French study. *Human Reproduction* **20**, 736–740.
- Asatiani K, von Eckardstein S, Simoni M *et al.* 2003 CAG repeat length in the androgen receptor gene affects the risk of male infertility. *International Journal of Andrology* **26**, 255–261.
- Aschim EL, Giwercman A, Stahl O *et al.* 2005 The RsaI polymorphism in the estrogen receptor-beta gene is associated with male infertility. *Journal of Clinical Endocrinology and Metabolism* **90**, 5343–5348.
- Bartoloni L, Cazzadore C, Ferlin A *et al.* 2004 Lack of the T54A polymorphism of the *DAZL* gene in infertile Italian patients. *Molecular Human Reproduction* **10**, 613–615.
- Becherini L, Guarducci E, Degl'Innocenti S *et al.* 2004 *DAZL* polymorphisms and susceptibility to spermatogenic failure: an example of remarkable ethnic differences. *International Journal of Andrology* **27**, 375–381.
- Bezold G, Lange M, Peter RU 2001 Homozygous methylenetetrahydrofolate reductase C677T mutation and male infertility. *New England Journal of Medicine* **344**, 1172–1173.
- Brown GM, Furlong RA, Sargent CA *et al.* 1998 Characterisation of the coding sequence and fine mapping of the human *DFFRY* gene and comparative expression analysis and mapping to the *Sxrb* interval of the mouse Y chromosome of the *Dffry* gene. *Human Molecular Genetics* **7**, 97–107.
- Brusco A, Michielotto C, Gatta V *et al.* 2006 The polymorphic polyglutamine repeat in the mitochondrial DNA polymerase gamma gene is not associated with oligozoospermia. *Journal of Endocrinological Investigation* **29**, 1–4.
- Carani C, Qin K, Simoni M *et al.* 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. *New England Journal of Medicine* **337**, 91–95.
- Carrell DT, Emery BR, Hammoud S 2007 Altered protamine expression and diminished spermatogenesis: what is the link? *Human Reproduction Update* **13**, 313–327.
- Deladoey J, Fluck C, Bex M *et al.* 1999 Aromatase deficiency caused by a novel *P450arom* gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. *Journal of Clinical Endocrinology and Metabolism* **84**, 4050–4054.
- Dowsing AT, Yong EL, Clark M *et al.* 1999 Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. *Lancet* **354**, 640–643.
- Ebisch I.M, van Heerde WL, Thomas CM *et al.* 2003 C677T methylenetetrahydrofolate reductase polymorphism interferes with the effects of folic acid and zinc sulfate on sperm concentration. *Fertility and Sterility* **80**, 1190–1194.
- Ferlin A, Vinanzi C, Garolla A *et al.* 2006 Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. *Clinical Endocrinology* **65**, 106–160.
- Foresta C, Garolla A, Bartoloni L *et al.* 2005 Genetic abnormalities among severely oligospermic men who are candidates for intracytoplasmic sperm injection. *Journal of Clinical Endocrinology and Metabolism* **90**, 152–156.
- Forti G, Krausz C 1998 Clinical review 100: Evaluation and treatment of the infertile couple. *Journal of Clinical Endocrinology and Metabolism* **83**, 4177–4188.
- Galan JJ, Guarducci E, Nuti F *et al.* 2007 Molecular analysis of estrogen receptor alpha gene AGATA haplotype and SNP12 in European populations: potential protective effect for cryptorchidism and lack of association with male infertility. *Human Reproduction* **22**, 444–449.
- Galan JJ, Buch B, Cruz N *et al.* 2005 Multilocus analyses of estrogen-related genes reveal involvement of the *ESR1* gene in male infertility and the polygenic nature of the pathology. *Fertility and*

- Sterility* **84**, 910–918.
- Gennari L, Merlotti D, De Paola V *et al.* 2005 Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. *American Journal of Epidemiology* **161**, 307–320.
- Giachini C, Guarducci E, Longepied G *et al.* 2005 The gr/gr deletion(s): a new genetic test in male infertility? *Journal of Medical Genetics* **42**, 497–502.
- Gottlieb B, Beitel LK, Wu JH, Trifiro M 2004 The androgen receptor gene mutations database (ARDB). *Human Mutation* **23**, 527–533. <http://androgendb.mcgill.ca/> [accessed 19 November, 2007].
- Guarducci E, Nuti F, Becherini L *et al.* 2006 Estrogen receptor alpha promoter polymorphism: stronger estrogen action is coupled with lower sperm count. *Human Reproduction* **21**, 994–1001.
- Harris TP, Gomas KP, Weir F *et al.* 2006 Molecular analysis of polymerase gamma gene and mitochondrial polymorphism in fertile and subfertile men. *International Journal of Andrology* **29**, 421–433.
- Huhtaniemi I 2006 Mutations along the pituitary–gonadal axis affecting sexual maturation: novel information from transgenic and knockout mice. *Molecular and Cellular Endocrinology* **25**, 254–255.
- Iguchi N, Yang S, Lamb DJ, Hecht NB 2005 An SNP in protamine 1: a possible genetic cause of male infertility? *Journal of Medical Genetics* **43**, 382–384.
- Jensen M, Leffers H, Petersen JH *et al.* 2004 Frequent polymorphism of the mitochondrial DNA polymerase gamma gene (POLG) in patients with normal spermograms and unexplained subfertility. *Human Reproduction* **19**, 65–70.
- Krausz C, Degl'Innocenti S 2006 Y chromosome and male infertility: update, 2006. *Frontiers in Bioscience* **11**, 3049–3061.
- Krausz C, Giachini C 2007 Genetic risk factors in male infertility. *Archives of Andrology* **53**, 125–133.
- Krausz C, Degl'Innocenti S, Nuti F *et al.* 2006 Natural transmission of *USP9Y* gene mutations: a new perspective on the role of *AZF*a genes in male fertility. *Human Molecular Genetics* **15**, 2673–2681.
- Krausz C, Guarducci E, Becherini L *et al.* 2004 The clinical significance of the *POLG* gene polymorphism in male infertility. *Journal of Clinical Endocrinology and Metabolism* **89**, 4292–4297.
- Krausz C, Forti G, McElreavey K 2003 The Y chromosome and male fertility and infertility. *International Journal of Andrology* **26**, 70–75.
- Kukuvitis A, Georgiou I, Bouba I *et al.* 2002 Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. *International Journal of Andrology* **25**, 149–152.
- Kusz K, Ginter-Matuszewska B, Ziolkowska K *et al.* 2007 Polymorphisms of the human *PUMILIO2* gene and male sterility. *Molecular Reproduction and Development* **74**, 795–799.
- Lau YF 1999 Gonadoblastoma, testicular and prostate cancers, and the *TSPY* gene. *American Journal of Human Genetics* **64**, 921–927.
- Lee K, Haugen HS, Clegg CH, Braun RE 1995 Premature translation of protamine 1 mRNA causes precocious nuclear condensation and arrests spermatid differentiation in mice. *Proceedings of the National Academy of Sciences of the United States of America* **92**, 12451–12455.
- Lepretre AC, Patrat C, Jouannet P, Bienvu T 2004 Mutation analysis of the *BOULE* gene in men with non-obstructive azoospermia: identification of a novel polymorphic variant in the black population. *International Journal of Andrology* **27**, 301–303.
- Lin YW, Hsu LC, Kuo PL *et al.* 2007 Partial duplication at *AZFc* on the Y chromosome is a risk factor for impaired spermatogenesis in Han Chinese in Taiwan. *Human Mutation* **28**, 486–494.
- Luconi M, Forti G, Baldi E 2002 Genomic and nongenomic effects of estrogens: molecular mechanisms of action and clinical implications for male reproduction. *Journal of Steroid Biochemistry and Molecular Biology* **80**, 369–381.
- Lundin KB, Giwercman A, Dizzey N, Giwercman YL 2007 Functional *in vitro* characterisation of the androgen receptor GGN polymorphism. *Molecular and Cellular Endocrinology* **264**, 184–187.
- Maffei L, Murata Y, Rochira V *et al.* 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. *Journal of Clinical Endocrinology and Metabolism* **89**, 61–70.
- Martinez J, Bonache S, Carvajal A *et al.* 2007 Mutations of *SYCP3* are rare in infertile Spanish men with meiotic arrest. *Fertility and Sterility* **88**, 988–989.
- Martinez-Heredia J, Estanyol JM, Balleca JL, Oliva R 2006 Proteomic identification of human sperm proteins. *Proteomics* **6**, 4356–4369.
- Matzuk MM, Lamb DJ 2002 Genetic dissection of mammalian fertility pathways. *Nature Cell Biology* **4**, 41–49.
- McElreavey K, Krausz C 1999 Sex Chromosome Genetics 99. Male infertility and the Y chromosome. *American Journal of Human Genetics* **64**, 928–933.
- Miyamoto T, Hasuike S, Yogev L *et al.* 2003 Azoospermia in patients heterozygous for a mutation in *SYCP3*. *Lancet* **362**, 1714–1719.
- Morishima A, Grumbach MM, Simpson ER *et al.* 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. *Journal of Clinical Endocrinology and Metabolism* **80**, 3689–3698.
- Noordam MJ, Repping S 2006 The human Y chromosome: a masculine chromosome. *Current Opinion in Genetics and Development* **16**, 225–232.
- O'Donnell L, Robertson KM, Jones ME, Simpson ER 2001 Estrogen and spermatogenesis. *Endocrine Reviews* **22**, 289–318.
- Ostermeier GC, Dix DJ, Miller D *et al.* 2002 Spermatozoal RNA profiles of normal fertile men. *Lancet* **360**, 772–777.
- Paduch DA, Mielnik A, Schlegel PN 2005 Novel mutations in testis-specific ubiquitin protease 26 gene may cause male infertility and hypogonadism. *Reproductive BioMedicine Online* **10**, 747–754.
- Park JH, Lee HC, Jeong YM, *et al.* 2005 MTHFR C677T polymorphism associates with unexplained infertile male factors. *Journal of Assisted Reproduction and Genetics* **22**, 361–368.
- Platts AE, Dix DJ, Chemes HE *et al.* 2007 Success and failure in human spermatogenesis as revealed by teratozoospermic RNAs. *Human Molecular Genetics* **16**, 763–773.
- Quigley CA, De Bellis A, Marschke KB *et al.* 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. *Endocrine Reviews* **16**, 271–321.
- Rajender S, Singh L, Thangaraj K 2007 Phenotypic heterogeneity of mutations in androgen receptor gene. *Asian Journal of Andrology* **9**, 147–179.
- Rajpert-De Meyts E, Leffers H *et al.* 2002 CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men. *Lancet* **359**, 44–46.
- Ravel C, Chantot-Bastaraud S, El Houate B *et al.* 2007 Mutations in the *protamine 1* gene associated with male infertility. *Molecular Human Reproduction* **13**, 461–464.
- Ravel C, El Houate B, Chantot S *et al.* 2006 Haplotypes, mutations and male fertility: the story of the testis-specific ubiquitin protease *USP26*. *Molecular Human Reproduction* **12**, 643–646.
- Reijo R, Lee TY, Salo P *et al.* 1995 Diverse spermatogenic defects in humans caused by Y chromosome deletions encompassing a novel RNA-binding protein gene. *Nature Genetics* **10**, 383–393.
- Repping S, van Daalen SK, Brown LG *et al.* 2006 High mutation rates have driven extensive structural polymorphism among human Y chromosomes. *Nature Genetics* **38**, 463–467.
- Repping S, Skaletsky H, Brown L *et al.* 2003 Polymorphism for a 1.6-Mb deletion of the human Y chromosome persists through balance between recurrent mutation and haploid selection. *Nature Genetics* **35**, 247–251.
- Reynolds N, Collier B, Bingham V *et al.* 2007 Translation of the synaptonemal complex component *Sycp3* is enhanced *in vivo* by the germ cell specific regulator *Dazl*. *RNA* **13**, 974–981.
- Rovio AT, Marchington DR, Donat S *et al.* 2001 Mutations at the mitochondrial DNA polymerase (*POLG*) locus associated with male infertility. *Nature Genetics* **29**, 261–262.
- Singh K, Singh SK, Sah R *et al.* 2005 Mutation C677T in the methylenetetrahydrofolate reductase gene is associated with male infertility in an Indian population. *International Journal of*

- Andrology* **28**, 115–119.
- Singh R, Deepa SR, Madhavi S *et al.* 2006 Male infertility: no evidence of involvement of androgen receptor gene among Indian men. *Journal Andrology* **27**, 102–105.
- Skaletsky H, Kuroda-Kawaguchi T, Minx PJ *et al.* 2003 The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature* **423**, 825–837.
- Smith EP, Boyd J, Frank GR *et al.* 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. *New England Journal of Medicine* **331**, 1056–1061.
- Stern LL, Mason JB, Selhub J, Choi SW 2000 Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. *Cancer, Epidemiology Biomarkers and Prevention* **9**, 849–853.
- Stouffs K, Lissens W, Tournaye H *et al.* 2006a Alterations of the *USP26* gene in Caucasian men. *International Journal of Andrology* **29**, 614–617.
- Stouffs K, Willems A, Lissens W, *et al.* 2006b The role of the testis-specific gene *hTAF7L* in the aetiology of male infertility. *Molecular Human Reproduction* **12**, 263–267.
- Stouffs K, Lissens W, Tournaye H *et al.* 2005a *SYCP3* mutations are uncommon in patients with azoospermia. *Fertility and Sterility* **84**, 1019–1020.
- Stouffs K, Lissens W, Tournaye H *et al.* 2005b Possible role of *USP26* in patients with severely impaired spermatogenesis. *European Journal of Human Genetics* **13**, 336–340.
- Stupia L, Gatta V, Scarciolla O *et al.* 2003 The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and male infertility in Italy. *Journal of Endocrinological Investigation* **26**, 620–622.
- Sun C, Skaletsky H, Birren B *et al.* 1999 An azoospermic man with a *de novo* point mutation in the Y-chromosomal gene *USP9Y*. *Nature Genetics* **23**, 429–432.
- Suzuki Y, Sasagawa I, Itoh K *et al.* 2002 Estrogen receptor alpha gene polymorphism is associated with idiopathic azoospermia. *Fertility and Sterility* **78**, 1341–1343.
- Tanaka H, Miyagawa Y, Tsujimura A *et al.* 2003 Single nucleotide polymorphisms in the protamine-1 and -2 genes of fertile and infertile human male populations. *Molecular Human Reproduction* **9**, 69–73.
- Teng YN, Lin YM, Sun HF *et al.* 2006 Association of *DAZL* haplotypes with spermatogenic failure in infertile men. *Fertility and Sterility* **86**, 129–135.
- Teng YN, Lin YM, Lin YH *et al.* 2002 Association of a single-nucleotide polymorphism of the deleted-in-azoospermia-like gene with susceptibility to spermatogenic failure. *Journal of Clinical Endocrinology and Metabolism* **87**, 5258–5264.
- Trarbach EB, Silveira LG, Latronico AC 2007 Genetic insights into human isolated gonadotropin deficiency. *Pituitary* **10**, 381–391.
- Tschanter P, Kostova E, Luetjens CM *et al.* 2004 No association of the A260G and A386G *DAZL* single nucleotide polymorphisms with male infertility in a Caucasian population. *Human Reproduction* **19**, 2771–2776.
- Tung JY, Rosen MP, Nelson LM *et al.* 2006a Variants in deleted in azoospermia-like (*DAZL*) are correlated with reproductive parameters in men and women. *Human Genetics* **118**, 730–740.
- Tung JY, Rosen MP, Nelson LM *et al.* 2006b Novel missense mutations of the deleted-in-azoospermia-like (*DAZL*) gene in infertile women and men. *Reproductive Biology and Endocrinology* **4**, 40.
- Tut TG, Ghadessy FJ, Trifiro MA *et al.* 1997 Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production, and male infertility. *Journal of Clinical Endocrinology and Metabolism* **82**, 3777–3782.
- Vodicka R, Vrtel R, Dusek L *et al.* 2007 *TSPY* gene copy number as a potential new risk factor for male infertility. *Reproductive BioMedicine Online* **14**, 579–587.
- Vogt PH, Edelman A, Kirsch S *et al.* 1996 Human Y chromosome azoospermia factors (AZF) mapped to different subregions in Yq11. *Human Molecular Genetics* **5**, 933–943.
- von Eckardstein S, Syska A, Gromoll J *et al.* 2001 Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. *Journal of Clinical Endocrinology and Metabolism* **86**, 2585–2590.
- Wang PJ 2004 X chromosomes, retrogenes and their role in male reproduction. *Trends in Endocrinology and Metabolism* **15**, 79–83.
- Wang PJ, McCarrey JR, Yang F, Page DC 2001 An abundance of X-linked genes expressed in spermatogonia. *Nature Genetics* **27**, 422–426.
- Westerveld GH, Repping S, Leschot NJ *et al.* 2005a Mutations in the human *BOULE* gene are not a major cause of impaired spermatogenesis. *Fertility and Sterility* **83**, 513–515.
- Westerveld GH, Repping S, Lombardi MP, van der Veen F 2005b Mutations in the chromosome pairing gene *FKBP6* are not a common cause of non-obstructive azoospermia. *Molecular Human Reproduction* **11**, 673–675.
- Yatsenko AN, Roy A, Chen R *et al.* 2006 Non-invasive genetic diagnosis of male infertility using spermatozoal RNA: *KLHL10* mutations in oligozoospermic patients impair homodimerization. *Human Molecular Genetics* **15**, 3411–3419.
- Yen PH 2004 Putative biological functions of the *DAZ* family. *International Journal of Andrology* **27**, 125–129.
- Yen PH, Chai NN, Salido EC 1996 The human autosomal gene *DAZLA*: testis specificity and a candidate for male infertility. *Human Molecular Genetics* **5**, 2013–2017.
- Yoshida R, Fukami M, Sasagawa I *et al.* 2005 Association of cryptorchidism with a specific haplotype of the estrogen receptor alpha gene: implication for the susceptibility to estrogenic environmental endocrine disruptors. *Journal of Clinical Endocrinology and Metabolism* **90**, 4716–4721.
- Yuan L, Liu JG, Zhao J *et al.* 2000 The murine *SCP3* gene is required for synaptonemal complex assembly, chromosome synapsis, and male fertility. *Molecular Cell* **5**, 73–83.
- Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E 2004 X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. *Journal of Clinical Endocrinology and Metabolism* **89**, 6208–6217.

Received 1 July 2007; refereed 30 August 2007; accepted 28 September 2007.